A Study on Enumeration of Factors Prone to the Development of COVID-19-Associated Mucormycosis

被引:0
|
作者
Velusamy, Sivakumar [1 ,3 ]
Rajagopal, Jayakumar [2 ]
Jayakumar, Jessica [1 ]
Parthiban, Dharshini [1 ]
Hussain, Adeeb Ismail Zahir [1 ]
机构
[1] PSG Coll Pharm, Dept Pharm Practice, Coimbatore, Tamil Nadu, India
[2] PSG Inst Med Sci & Res, Dept Resp Med, Coimbatore, Tamil Nadu, India
[3] PSG Coll Pharm, Dept Pharm Practice, Coimbatore 641004, Tamil Nadu, India
来源
关键词
CAM; hypoxia; increasing age; hyperglycemia; inflammation; steroids; COVID-19; MANAGEMENT; INDIA;
D O I
10.1055/s-0043-1769582
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Patients with pre-existing chronic medical conditions with altered immunity are prone to COVID-19-associated mucormycosis (CAM).Objective In this study, our objectives were to identify the risk factors that increase the chances of developing CAM and to determine the severity of the risk factors of CAM. Thereby, we can optimize the modifiable risk factors for developing CAM in coronavirus disease 2019 (COVID-19) patients. For instance, better control of blood glucose levels in COVID-19 patients can decrease the risk of developing CAM.Materials and Methods The data was collected retrospectively from 1000 COVID-19 infected patients, above the age of 18 years during the time period of March 2021 to August 2021, in which 86 patients had confirmed CAM.Statistical Analysis Binary logistic regression and curve estimation analysis were performed using SPSS software version 29 for identifying the associated risk factors of CAM with the significance of p -value less than 0.05.Results Factors such as severe inflammation ( p = 0.048), high dose of steroid administration ( p = 0.005), increasing age ( p < 0.001), and prolonged hospital stay ( p < 0.001) were statistically proven to be significant risk factors, associated with CAM.Conclusion Increasing age, severe inflammation, high dose of steroid administration, and prolonged hospital stay have association with occurrence of CAM.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [1] COVID-19-associated mucormycosis and treatments
    Subramaniyan, Vetriselvan
    Fuloria, Shivkanya
    Darnal, Hari Kumar
    Meenakshi, Dhanalekshmi Unnikrishnan
    Sekar, Mahendran
    Bin Nordin, Rusli
    Chakravarthi, Srikumar
    Sathasivam, Kathiresan V.
    Khan, Shah Alam
    Wu, Yuan Seng
    Kumari, Usha
    Sudhakar, Kalvatala
    Malviya, Rishabha
    Sharma, Vipin Kumar
    Fuloria, Neeraj Kumar
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2021, 14 (09) : 401 - 409
  • [2] COVID-19-associated mucormycosis and treatments
    Vetriselvan Subramaniyan
    Shivkanya Fuloria
    Hari Kumar Darnal
    Dhanalekshmi Unnikrishnan Meenakshi
    Mahendran Sekar
    Rusli Bin Nordin
    Srikumar Chakravarthi
    Kathiresan V.Sathasivam
    Shah Alam Khan
    Yuan Seng Wu
    Usha Kumari
    Kalvatala Sudhakar
    Rishabha Malviya
    Vipin Kumar Sharma
    Neeraj Kumar Fuloria
    Asian Pacific Journal of Tropical Medicine, 2021, 14 (09) : 401 - 409
  • [3] COVID-19-Associated Pulmonary Mucormycosis
    Krishna, Vidya
    Bansal, Nitin
    Morjaria, Jaymin
    Kaul, Sundeep
    JOURNAL OF FUNGI, 2022, 8 (07)
  • [4] Epidemiology of COVID-19-Associated Mucormycosis
    Tayabali, Khadija
    Pothiwalla, Hussein
    Narayanan, Shivakumar
    CURRENT FUNGAL INFECTION REPORTS, 2023, 17 (02) : 156 - 175
  • [5] COVID-19-associated Mucormycosis: A clinico-epidemiological study
    Chakravarty, Jaya
    Gupta, Munesh Kumar
    Tilak, Ragini
    Kumar, Rajesh
    Maurya, Rajendra Prakash
    Kumar, Nilesh
    Aggarwal, Susheel Kumar
    Shiva, S.
    Sharma, Naresh Kumar
    Dhiman, Neeraj Kumar
    Chaubey, Manaswi
    Singh, Vishambhar
    Verma, Ashish
    Banerjee, Tuhina
    Agrawal, Neeraj Kumar
    Prasad, Ravi Shankar
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (09)
  • [6] Rhinocerebral mucormycosis: A clinicopathological analysis of COVID-19-associated mucormycosis
    Bahal, Neelima
    Piyush, A. R.
    Kala, Pooja Sharma
    Dogra, Shruti
    Thapliyal, Naveen
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (08) : 3257 - 3263
  • [7] Prevention and Treatment of COVID-19-Associated Mucormycosis
    Kevin T. Grafmiller
    Jivianne T. Lee
    Current Treatment Options in Allergy, 2023, 10 : 83 - 92
  • [8] Prevention and Treatment of COVID-19-Associated Mucormycosis
    Grafmiller, Kevin T.
    Lee, Jivianne T.
    CURRENT TREATMENT OPTIONS IN ALLERGY, 2023, 10 (02) : 83 - 92
  • [9] COVID-19-associated mucormycosis and evolving evidence
    Sarda, R.
    Swain, S.
    Ray, A.
    Wig, N.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2022, 115 (06) : 422 - 422
  • [10] COVID-19-associated mucormycosis involving the maxilla
    Hasheminasab, Mahboube
    Karizmeh, Mojtaba Salehi
    Sharifi, Reza
    Beshkar, Majid
    Matloubi, Narges
    Asadi, Amir Ali
    Nazar, Elham
    CLINICAL CASE REPORTS, 2022, 10 (08):